Plus Therapeutics (NASDAQ:PSTV) Issues Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:PSTV) announced its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. The business had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million.

Plus Therapeutics Stock Performance

Shares of PSTV stock traded down $0.35 during mid-day trading on Friday, hitting $1.17. The company’s stock had a trading volume of 2,155,444 shares, compared to its average volume of 3,920,618. The stock has a market cap of $6.90 million, a price-to-earnings ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.67. The business has a 50-day moving average price of $1.11 and a 200 day moving average price of $1.24.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PSTV shares. HC Wainwright reduced their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday. Ascendiant Capital Markets reduced their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Plus Therapeutics in a report on Friday.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.